Kontafarma China Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Kontafarma China Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	12.7%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?

Sep 15

Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?

Apr 20

Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?

Nov 04

Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares

Feb 18

These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively

Dec 07

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kontafarma China Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:1312 - Analysts future estimates and past financials data (HKD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	809	-29	N/A	N/A	N/A
9/30/2023	841	-12	N/A	N/A	N/A
6/30/2023	874	5	-23	21	N/A
3/31/2023	884	-40	-38	9	N/A
12/31/2022	894	-85	-54	-2	N/A
9/30/2022	997	-24	N/A	N/A	N/A
6/30/2022	869	-10	-6	60	N/A
3/31/2022	836	-29	-11	68	N/A
12/31/2021	803	-48	-16	75	N/A
6/30/2021	938	-119	-182	12	N/A
3/31/2021	974	-81	-78	110	N/A
12/31/2020	1,009	-42	26	207	N/A
6/30/2020	661	66	145	228	N/A
3/31/2020	791	60	43	127	N/A
12/31/2019	921	54	-59	26	N/A
9/30/2019	1,280	29	-6	72	N/A
6/30/2019	1,666	22	47	118	N/A
3/31/2019	1,880	27	21	93	N/A
12/31/2018	2,094	32	-5	67	N/A
9/30/2018	1,985	12	-74	7	N/A
6/30/2018	1,876	-8	-143	-53	N/A
3/31/2018	1,610	-5	-141	-50	N/A
12/31/2017	1,344	-2	-139	-47	N/A
9/30/2017	1,175	-15	N/A	-68	N/A
6/30/2017	1,006	-27	N/A	-89	N/A
3/31/2017	820	-32	N/A	-38	N/A
12/31/2016	633	-37	N/A	12	N/A
9/30/2016	539	-43	N/A	-16	N/A
6/30/2016	445	-49	N/A	-43	N/A
3/31/2016	456	-41	N/A	-72	N/A
12/31/2015	466	-34	N/A	-100	N/A
9/30/2015	547	-18	N/A	-36	N/A
6/30/2015	628	-2	N/A	28	N/A
3/31/2015	681	8	N/A	10	N/A
12/31/2014	733	17	N/A	-8	N/A
9/30/2014	747	28	N/A	-40	N/A
6/30/2014	761	38	N/A	-72	N/A
3/31/2014	732	35	N/A	-68	N/A
12/31/2013	703	33	N/A	-64	N/A
9/30/2013	685	27	N/A	-73	N/A
6/30/2013	667	22	N/A	-81	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1312's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if 1312's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 1312's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1312's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 1312's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1312's Return on Equity is forecast to be high in 3 years time

Kontafarma China Holdings Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Kontafarma China Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Tongfang Kontafarma Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Tongfang Kontafarma Holdings Limited Provides Earnings Guidance for the Full Year of Fiscal 2020

Recent updates

New minor risk - Share price stability

Kontafarma China Holdings Limited Announces Management Changes, Effect from 19 April 2024

Full year 2023 earnings released: HK$0.005 loss per share (vs HK$0.015 loss in FY 2022)

Kontafarma China Holdings Limited, Annual General Meeting, Jun 07, 2024

Kontafarma China Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Health Check: How Prudently Does Kontafarma China Holdings (HKG:1312) Use Debt?

First half 2023 earnings released: EPS: HK$0.007 (vs HK$0.009 loss in 1H 2022)

Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Kontafarma China Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

New major risk - Share price stability

Kontafarma China Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Full year 2022 earnings released: HK$0.015 loss per share (vs HK$0.003 loss in FY 2021)

Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Less than half of directors are independent

Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?

First half 2022 earnings released: HK$0.011 loss per share (vs HK$0.014 loss in 1H 2021)

Tongfang Kontafarma Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Tongfang Kontafarma Holdings Limited to Report First Half, 2022 Results on Aug 29, 2022

Less than half of directors are independent

Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?

Tongfang Kontafarma Holdings Limited Announces Management Changes

Full year 2021 earnings released: HK$0.003 loss per share (vs HK$0.008 loss in FY 2020)

Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?

Executive Director Bingzhang Wei has left the company

Less than half of directors are independent

Tongfang Kontafarma Holdings Limited Provides Earnings Guidance for the Full Year of Fiscal 2020

Tongfang Kontafarma Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares

These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively

Minyi Holdings Limited entered into an agreement to acquire Real Jade Limited from Tongfang Kontafarma Holdings Limited (SEHK:1312) for approximately HKD 350 million.

First half earnings released

First half earnings released

Tongfang Kontafarma Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies